Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company ADC Therapeutics S.a.r.l.
DescriptionMAB against prostate-specific membrane antigen (PSMA; FOLH1; GCPII) linked with a pyrrolobenzodiazepine (PBD) warhead
Molecular Target Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationProstate cancer
Indication DetailsTreat castration-resistant prostate cancer
Regulatory Designation
PartnerAstraZeneca plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today